03 October 2013

Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules

Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial

-Mitchell L Jones, et al.
Expert Opinion on Biological Therapy, Informa Healthcare. Posted online on September 28, 2013. (doi:10.1517/14712598.2013.833601)
http://informahealthcare.com/doi/abs/10.1517/14712598.2013.833601

Excerpt:
  • Results: Subjects receiving L. reuteri NCIMB 30242 reported significant improvements in general GI health status (p = 0.029) and in symptoms related to diarrhea (p = 0.018) as compared to placebo over the intervention period. Further, a greater proportion of L. reuteri-treated subjects showed improved general GI health status (p = 0.042) and improved diarrhea symptoms (p = 0.03).
  • Conclusions: L. reuteri NCIMB 30242 capsules appear to be well tolerated and potentially beneficial for GI health status. This BSH active probiotic bacterial cells can be used alone or in combination with others such as health food, drug calcium, vitamins and others to treat and/or prevent gastrointestinal associated disorders. Further clinical investigation is warranted for the treatment of functional GI disorders.